



Technical Report No. 60-3

Process Validation: A Lifecycle Approach

Annex 2: Biopharmaceutical Drug Substances
Manufacturing

Process Validation: A Lifecycle Approach Team

Authors and Contributors

Rebecca A. Devine, PhD, Independent Regulatory Consultant, Co-leader

Udesh de Silva, PhD, Samsung Biologics, Co-leader

Ronald Bates, PhD, Bristol-Meyers-Squibb

Igoris Čajevskis, Merck & Co., Inc.

Vijay Chiruvolu, PhD, Instil Bio

Lara Collier, Genentech, a member of the Roche Group

Michael R. De Felippis, PhD, Eli Lilly and Company, Inc.

Monica Lent, Genentech, a member of the Roche Group

John McShane, Validant

Morten Munk, Fujifilm Diosynth Biotechnologies

Randi Saunders, PhD, Merck & Co., Inc.

Ken Wong, Sanofi-Pasteur

Zhaoli Zhou, PhD, Independent Consultant

Wendy Zwolenski-Lambert, Novartis AG

Process Validation: A Lifecycle Approach

Annex 2: Biopharmaceutical Drug Substances Manufacturing

Technical Report No. 60-3

ISBN: 978-1-945584-24-4

© 2021 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	1	5.0 STAGE 3: LIFECYCLE MANAGEMENT	33
1.1 Purpose and Scope	1	5.1 Ongoing Process Verification Approaches	33
2.0 GLOSSARY OF TERMS.....	2	5.2 Transfer of Biopharmaceutical Manufacturing Processes	34
2.1 Abbreviations.....	6	5.2.1 Process Transfer and Adaptation	34
3.0 STAGE 1: BUILDING AND CAPTURING PROCESS KNOWLEDGE — PROCESS DESIGN	6	5.2.2 Product Comparability and Stability	35
3.1 Sequence of Activities Leading Up to Stage 2 – Process Performance Qualification	7	5.2.3 Multisite Manufacturing of Biopharmaceutical Products.....	35
3.2 Analytical Methods	7	6.0 REFERENCES.....	35
3.3 Risk Assessments	9	7.0 APPENDIX 1: EXAMPLE OF FAILURE MODES AND EFFECTS ANALYSIS.....	39
3.4 Platform Technology Application during Development	10	8.0 APPENDIX 2: EXAMPLE OF SCALE-DOWN MODEL QUALIFICATION	40
3.5 Quality Target Product Profile and Critical Quality Attribute Assignment	10	9.0 APPENDIX 3: UNIT OPERATIONS USED IN BIOPHARMA PROCESSES	41
3.6 Control Strategy	12	9.1 Expression Construct and Cell-Line Development and Characterization	41
3.6.1 Risk Assessment to Support Control Strategy Development	13	9.2 Vial Thaw and Cell Expansion (Seed Train)	41
3.6.2 Critical Process Parameters	13	9.3 Production Bioreactor (Fermentation/Cell Culture)	41
3.6.3 Noncritical Process Parameters	13	9.4 Cell Culture	42
3.6.4 Process Characterization	14	9.5 Harvest.....	43
3.6.5 Criticality Assessment of Raw Materials	16	9.6 Capture Chromatography	43
4.0 STAGE 2: PROCESS QUALIFICATION.....	17	9.7 Viral Inactivation	43
4.1 Readiness	18	9.8 Polishing Chromatography.....	43
4.1.1 Equipment and Facilities.....	18	9.9 Ultrafiltration and Diafiltration	45
4.1.2 Methods	19	9.10 Drug Substance Filling	45
4.1.3 Raw Materials	19	9.11 Single-use Bioreactor Cell Culture	45
4.2 Process Validation	20	9.12 Reactions	45
4.2.1 Process Performance Qualification.....	20	9.13 Conjugation (e.g., Drug, Vaccine).....	45
4.2.2 Process Validation Studies.....	23		
4.2.3 Validation of Single-Use Systems.....	32		

FIGURES AND TABLES INDEX

Table 3.2-1 Examples of In-Process Test and Lot Release Assays	8	Table 9.6-1 Example: Process Parameters and Performance Indicators.....	44
Figure 4.0-1 Activities Leading Up to Process Validation ..	18	Table 9.7-1 Example: Process Parameters and Performance Indicators.....	44
Table 7.0-1 Example FMEA: Failure Modes and Effects Analysis	39	Table 9.8-1 Example: Process Parameters and Performance Indicators.....	44
Table 8.0-1 Scale-Down Variables	40	Table 9.9-1 Example: Process Parameters and Performance Indicators.....	45
Table 8.0-2 Chromatography Column Scale-Down Verification Example	40	Table 9.10-1 Example: Process Parameters and Performance Indicators.....	45
Table 9.2-1 Example: Process Parameters and Performance Indicators.....	42	Table 9.12-1 Example: Process Parameters and Performance Indicators.....	46
Table 9.3-1 Example: Process Parameters and Performance Indicators.....	42	Table 9.13-1 Example: Process Parameters and Performance Indicators.....	46
Table 9.4-1 Example: Process Parameters and Performance Indicators.....	42		
Table 9.5-1 Example: Process Parameters and Performance Indicators.....	43		



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org